AtriCure, Inc. (ATRC) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Positive FCF ⢠High valuation risk Aterian shows strong liquidity, positive free cash flow and improving quarterly operating results alongside very high gross margins and low leverage, but FY operating losses, elevated opex, large intangibles/retained deficit and stretched valuation create significant execution risk.
Price Behavior
Key Price Behavior Insights: ⢠Mild downtrend ⢠Support defended ⢠Resistance overhead Support Level: $28.00â$28.30 Resistance Level: $30.00â$30.50 ATRC is in a mild short-term downtrendâprice fell ~4â5% to $28.23 (~3% below last month's ~$29.10 SMA), holding $28.00â$28.30 support but facing resistance near $30.00â$30.50 with elevated volatility.
Sentiment & News
Key News Insights: ⢠Modest insider trim ⢠5,000 shares sold ⢠No other headlines AtriCure's CSO sold 5,000 shares (~$149K) on 2026-03-12, trimming his direct stake by ~4.9% in a routine insider sale reported 2026-03-18.
AI Summary
ATRC has demonstrably shifted from a cashâhungry clinical story to a cashâgenerative, commercialization company (positive Q4 net income, FCF â $48M, strong gross margins), but that reârating is conditional on management sustaining margin discipline while avoiding clinical/competitive setbacks. Actionable trigger: watch for repeatable quarterly profitability and upcoming LeAAPS/BoxXâNoAF readoutsâfailure to repeat Q4 or adverse trial/PFA adoption will quickly reverse the thesis given stretched valuation.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |